Navigation Links
BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

- First in human clinical data highlight safety profile of BSI-201 in

subjects with advanced solid tumors -

BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data supporting its lead PARP inhibitor, BSI-201, will be presented at the 2008 American Society of Clinical Oncology annual meeting in Chicago.

Findings will be presented from the first in human Phase 1 study of BSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as a monotherapy in subjects with advanced solid tumors. BiPar will also present a Phase 1b study evaluating BSI-201 in combination with topotecan, gemcitabine, temozolomide and carboplatin/paclitaxel in subjects with advanced solid tumors. The primary objective of these respective studies is to assess the safety profile of BSI-201 when used as a monotherapy and in combination with cytotoxic chemotherapy in subjects with measurable disease.

The schedule of poster presentations is as follows:

Title: First in Human Phase 1 Study of BSI-201, a Small Molecule

Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with

Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract#: 3577

Title: A Phase 1B Study Evaluating BSI-201 in Combination with

Chemotherapy in Subjects with Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract #: 3579

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
6. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... WHIPPANY, N.J. , Sept. 1, 2017  Bayer will ... at the European Society for Medical Oncology (ESMO) 2017 Congress, ... studies presented will include new preclinical and clinical data on ... from two earlier pipeline projects. ... of the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
(Date:8/28/2017)... Aug. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Monday, September 11, 2017, in New York ... officer, is scheduled to present at 11:05 a.m. Eastern Time. ... at http://ir.hill-rom.com/events.cfm . A recorded replay will be available ... December 10, 2017. ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... ... Driving Dynamics Inc., announced today it has been selected as a 2017 ... its mission to continually monitor the training marketplace for the best providers of training ... and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... 2017 , ... Spain’s popular line of health and wellness ... to RonnieColemanNutrition.com. , ACPG Laboratories has been in business for more than ... on the healing properties of plants, a proven science known as phytotherapy. ...
(Date:9/19/2017)... ... 2017 , ... For decades doctors, nurses, and other healthcare providers have been ... factors and calculating their cardiovascular disease (CVD) risk in the next 10 years. ... predicted today: an estimated 10-year risk prediction! , Imagine if the weatherman says there ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... the country with the Davidson Fellows Scholarship on September 27 at a reception ... in Science, Technology, Engineering, Mathematics, Literature and Music. , “I am honored to ...
(Date:9/19/2017)... ... 19, 2017 , ... Emergency nursing expertise, skill set, and ... (CEN®) certification according to a large-scale study announced today by the Board ... the Human Resources Research Organization (HumRRO) in late 2016 and early 2017, included ...
Breaking Medicine News(10 mins):